Orchard Foods (ORCH) — Subordinated Notes 8.25%
Executive Summary
Demo purchase of $100M face of Subordinated Notes 8.25% at 94.0 (cash investment $94.5M): current yield 8.8%, yield to maturity 9.7%. Recommendation: HOLD. Credit score 67/100 (Moderate risk). Base-case IRR 10.5%, downside 7.3%, severe -6.3%; probability-weighted IRR 6.7% vs a 12% hurdle; weighted P(default) 15%; severe-case valuation recovery 39%. HOLD (do not size yet): Base-case IRR clears hurdle (10.5% vs ≥ 12.0%); Expected-cash-flow IRR (probability-weighted) clears hurdle (6.7% vs ≥ 12.0%); Principal protected in severe case (recovery ≥ price) (39 vs 94.0 vs recovery ≥ price).
Investment Thesis
Defensive end market but 4.3x net leverage and volume decline. The subordinated notes at 94 yield ~9.5% and are covered in all scenarios on EV, though this is a carry trade rather than a distressed idea.
The question: Does a 9.7% yield on a rank-4 unsecured claim compensate for 15% probability-weighted default risk and 61% severe-case loss?
Company Overview
Branded and private-label shelf-stable foods; volume-pressured but with strong cash conversion. HQ Cincinnati, OH; Consumer / Packaged Foods. FY2025A revenue $3.0B, EBITDA $480M (16.0% margin); total debt $2.2B, cash $150M. DEMO DATA
Industry / Market
Packaged food has seen volume declines as consumers trade down; defensive earnings but limited growth.
Historical Financial Performance
| $M | FY2022A | FY2023A | FY2024A | FY2025A |
|---|---|---|---|---|
| Revenue | $2.9B | $3.0B | $3.0B | $3.0B |
| % growth | 5.3% | 0.7% | -0.7% | |
| Direct costs / COGS | $2.0B | $2.1B | $2.1B | $2.1B |
| Gross profit (NOI for real estate) | $883.5M | $915.0M | $906.0M | $900.0M |
| % margin | 31.0% | 30.5% | 30.0% | 30.0% |
| Operating expenses (cash, adjusted) | $399.0M | $420.0M | $422.8M | $420.0M |
| EBITDA (company-adjusted basis) | $484.5M | $495.0M | $483.2M | $480.0M |
| % margin | 17.0% | 16.5% | 16.0% | 16.0% |
| D&A | $99.8M | $105.0M | $105.7M | $105.0M |
| Share-based compensation | $0.0M | $0.0M | $0.0M | $0.0M |
| EBIT | $384.8M | $390.0M | $377.5M | $375.0M |
| Interest expense | $130.6M | $138.3M | $146.0M | $153.7M |
| EBT | $254.1M | $251.7M | $231.5M | $221.3M |
| Taxes | $63.5M | $62.9M | $57.9M | $55.3M |
| Net income (model basis) | $190.6M | $188.8M | $173.6M | $166.0M |
| Capex | $85.5M | $90.0M | $90.6M | $90.0M |
| Working capital & other cash items | $3.4M | $18.0M | $2.4M | ($2.4M) |
| Free cash flow | $201.5M | $185.8M | $186.3M | $183.4M |
Capital Structure
| Tranche | Rank | Secured | Face value | Rate | Maturity | Mark / price |
|---|---|---|---|---|---|---|
| First-Lien Term Loan | 1 | Yes | $900.0M | S+335bp | 2029-05-31 | 99.0 |
| Senior Notes 5.50% | 3 | No | $800.0M | 5.50% | 2030-12-15 | 94.5 |
| Subordinated Notes 8.25% | 4 | No | $500.0M | 8.25% | 2031-09-15 | 94.0 |
Total debt $2.2B (4.6x EBITDA); net debt $2.0B; liquidity $150M; loan-to-value through the target tranche 71%.
Credit Analysis
Net leverage 4.3x, EBITDA / interest 3.12x, FCF / debt 8.3%, DSCR 2.1x, liquidity ratio 0.9x. Score components: Leverage 8/15, Coverage 8/15, Liquidity 3/10, Free cash flow 7/10, Maturity risk 10/10, Margin stability 10/10, Revenue stability 8/8, Asset coverage 8/12, Industry risk 5/10. Score change vs FY2024A (same capital structure): 68 → 67 (Interest coverage fell from 3.3x to 3.1x (-0.7 pts, negative); Liquidity ratio fell from 1.0x to 0.9x (-0.3 pts, negative)).
Debt Maturity Profile
| Period | Debt due | % of debt | Projected liquidity (Base) | Refinancing requirement |
|---|---|---|---|---|
| FY2029E | $900M | 41% | $902M | — |
| FY2030E | $800M | 36% | $291M | $509M |
| 2031 (beyond horizon) | $500M | 23% | $0M | $500M |
Risk flag: $800M maturity in FY2030E; only $291M projected liquidity; $509M refinancing requirement.
| Tranche | Matures | Balance at maturity | Cash on hand | Net lev. (test ≤) | Pro-forma coverage (test ≥) | Refi rate | Interest burden after | Result | Resolution |
|---|---|---|---|---|---|---|---|---|---|
| First-Lien Term Loan | FY2029E | $864.0M | $693M | 2.9x (8.5x) | 3.34x (1.20x) | 8.0% | $0.0M | REFINANCING PASS | Repaid from cash |
| Senior Notes 5.50% | FY2030E | $800.0M | $29M | 2.4x (8.5x) | 5.03x (1.20x) | 8.0% | $40.7M | REFINANCING PASS | Partly repaid from cash; remainder refinanced |
Base Case
Revenue CAGR 1.0%; FY2030E EBITDA $530M (16.8% margin); trough EBITDA $485M; peak net leverage 3.9x; minimum EBITDA / interest 3.16x; cumulative FCF $1.0B. No payment default modelled. IRR 10.5%, MOIC 1.32x.
Downside Case
Revenue CAGR -1.1%; FY2030E EBITDA $412M (14.5% margin); trough EBITDA $371M; peak net leverage 4.9x; minimum EBITDA / interest 2.26x; cumulative FCF $611M. No payment default modelled. IRR 7.3%, MOIC 1.21x.
Severe Downside
Revenue CAGR -4.9%; FY2030E EBITDA $286M (12.3% margin); trough EBITDA $233M; peak net leverage 8.4x; minimum EBITDA / interest 1.31x; cumulative FCF $171M. Payment default modelled in FY2029E; target-tranche recovery 39%. IRR -6.3%, MOIC 0.77x.
Covenant Analysis
| FY2026E | FY2027E | FY2028E | FY2029E | FY2030E | |
|---|---|---|---|---|---|
| Current metric | 3.86x | 3.39x | 2.92x | 2.45x | 1.90x |
| Covenant | ≤ 5.75x | ≤ 5.75x | ≤ 5.75x | ≤ 5.75x | ≤ 5.75x |
| Headroom | 1.89x (33%) | 2.36x (41%) | 2.83x (49%) | 3.30x (57%) | 3.85x (67%) |
| Status | PASS | PASS | PASS | PASS | PASS |
| FY2026E | FY2027E | FY2028E | FY2029E | FY2030E | |
|---|---|---|---|---|---|
| Current metric | 4.77x | 4.89x | 4.46x | 4.01x | 3.49x |
| Covenant | ≤ 5.75x | ≤ 5.75x | ≤ 5.75x | ≤ 5.75x | ≤ 5.75x |
| Headroom | 0.98x (17%) | 0.86x (15%) | 1.29x (22%) | 1.74x (30%) | 2.26x (39%) |
| Status | PASS | PASS | PASS | PASS | PASS |
Recovery Analysis
If the company defaults, recovery value is $1.7B (going concern) in the severe case → 39% recovery (61% LGD) on the target tranche; downside 100%. Recovery value = MAX(going concern $1.7B, liquidation $1.1B) + cash, less administrative costs; severe case struck at FY2029E.
| Claim (by seniority) | Rank | Claim | Recovery | Recovery % | Loss | Loss % |
|---|---|---|---|---|---|---|
| Recovery value | $1.7B | |||||
| Less: administrative / DIP costs | ($69.0M) | |||||
| First-Lien Term Loan | 1 | $645.2M | $645.2M | 100.0% | $0.0M | 0.0% |
| Senior Notes 5.50% | 3 | $811.0M | $811.0M | 100.0% | $0.0M | 0.0% |
| Subordinated Notes 8.25% | 4 | $510.3M | $200.3M | 39.3% | $310.0M | 60.7% |
| Total claims | $2.0B | $1.7B | $310.0M | |||
| Equity (residual) | $0.0M | Wiped out | ||||
Investment Returns
| Base Case | Downside | Severe Downside | |
|---|---|---|---|
| Face value / purchase price / cash investment | $100M / 94.0 / $94.5M UNDERWRITING ASSUMPTION | ||
| Cash interest + exit/recovery proceeds | $24.8M + $100.0M | $24.8M + $90.0M | $33.0M + $40.1M |
| Capital gain / (loss) vs purchase price | $6.0M | ($4.0M) | ($53.9M) |
| MOIC | 1.32x | 1.21x | 0.77x |
| IRR (hurdle 12%) | 10.5% | 7.3% | -6.3% |
Key Risks
- Refinancing: $800M maturity in FY2030E; only $291M projected liquidity; $509M refinancing requirement.
- Severe-case valuation recovery of 39% is below the 94.0 purchase price: a 61% loss given default.
- Severe case produces a payment default in FY2029E.
- Unsecured, rank 4: $1.7B of debt ranks ahead.
- Elevated leverage: net debt / EBITDA 4.3x.
Key Protections
- Coverage of 3.12x EBITDA / interest; EBITDA can fall 68% before coverage reaches 1.0x.
- Base-case refinancing tests pass for all 2 maturing tranche(s); 1 are repaid from cash.
- No covenant breach in the Downside case.
- Defensive demand
- Pricing power on brands
Catalysts
- Portfolio rationalization
- Commodity cost declines
Due Diligence Items
| Item | Status | Priority | Open question |
|---|---|---|---|
| Historical financials tied to filings | In Progress | High | Do model inputs reconcile to audited statements? |
| Quality of earnings / EBITDA add-backs | In Progress | High | How much of adjusted EBITDA is add-backs? |
| Supplier concentration | Issue Identified | Low | Any single-source dependencies? |
| Competitive position and management | Not Started | Medium | Share trend and management track record? |
| Debt documentation review | Not Started | High | Priming / drop-down protections and baskets? |
| Covenant package and definitions | Not Started | High | Covenant EBITDA definition and headroom? |
| Maturity profile and refinancing plan | In Progress | High | Is the refinancing plan credible at current leverage? |
| Collateral and lien perfection | In Progress | Medium | What assets secure the instrument? |
| Litigation and contingent liabilities | In Progress | Medium | Any material claims ahead of creditors? |
| Guarantees and structural subordination | In Progress | Medium | Which entities guarantee; any non-guarantor leakage? |
Recommendation
HOLD. HOLD (do not size yet): Base-case IRR clears hurdle (10.5% vs ≥ 12.0%); Expected-cash-flow IRR (probability-weighted) clears hurdle (6.7% vs ≥ 12.0%); Principal protected in severe case (recovery ≥ price) (39 vs 94.0 vs recovery ≥ price).
| Test | Actual | Required | Weight | |
|---|---|---|---|---|
| ✗ | Base-case IRR clears hurdle | 10.5% | ≥ 12.0% | core |
| ✗ | Expected-cash-flow IRR (probability-weighted) clears hurdle | 6.7% | ≥ 12.0% | core |
| ✓ | Downside IRR stays above floor | 7.3% | ≥ 0.0% | core |
| ✓ | Downside recovery meets minimum (valuation waterfall) | 100.0% | ≥ 60.0% | core |
| ✓ | Base-case refinancing succeeds | PASS | PASS | core |
| ✓ | Entry yield meets minimum | 9.7% | ≥ 9.0% | secondary |
| ✓ | Net leverage within maximum | 4.3x | ≤ 6.0x | secondary |
| ✓ | Covenant headroom (base case, minimum) | 32.9% | ≥ 15.0% | secondary |
| ✗ | Principal protected in severe case (recovery ≥ price) | 39 vs 94.0 | recovery ≥ price | secondary |
| ✗ | No unresolved high-priority diligence | 5 open | 0 open | secondary |
What would change my mind?
- EBITDA declines more than 68% from FY2025A (coverage < 1.0x) — or more than 26% (first covenant breaks).
- The entry price is above 90.5: the base case no longer earns the 12% hurdle (assumed price 94.0).
- Severe-case recovery returns the purchase price only if the distressed valuation multiple is at least 7.6x EBITDA (the severe case assumes 6.5x); the question is how much cushion we want.
- Collateral / enterprise value falls more than 27% from the base-case valuation: the tranche starts to take losses.
- Market access weakens: base-case pro-forma coverage at refinancing is 3.34x vs the 1.20x test, at an assumed 8.0% refinancing rate — a higher spread or lower EBITDA flips the test.
Sources (3)
| Source | Document | Data type | Period | Accession | Doc date | Retrieved | Class |
|---|---|---|---|---|---|---|---|
| CreditIQ demo dataset | Orchard Foods — illustrative financial statements FY2022–FY2025 | Income statement / cash flow | FY2022–FY2025 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Orchard Foods — illustrative capital structure & covenants | Debt schedule | As of 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Illustrative indicative bid marks (% of par) | Market price | 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
Generated entirely from the structured model (inputs → analysis → memo): every figure reconciles to the Excel workbook (see Settings → Reconciliation). Hypothetical terms are underwriting assumptions. Not investment advice.